Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 172Neoplasms 167Colorectal Neoplasms 154Neoplasm Metastasis 127Melanoma 119Recurrence 116Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 110Multiple Myeloma 103Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 82Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 76Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 64Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 54Sarcoma 52Uterine Cervical Neoplasms 51Myelodysplastic Syndromes 51Advanced Solid Tumors 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Deafness, Autosomal Recessive 39 × 1 year × Clear all
NCT04077099 2026-03-18

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
231 enrolled
Thoracic

Deafness, Autosomal Recessive 39, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡